



Host and Bacterial Factors Control Susceptibility of *Drosophila melanogaster* to *Coxiella burnetii* Infection

Reginaldo G. Bastos, Zachary P. Howard, Aoi Hiroyasu,  Alan G. Goodman

School of Molecular Biosciences, College of Veterinary Medicine, Washington State University, Pullman, Washington, USA

ABSTRACT *Coxiella burnetii* is the causative agent of Q fever, a zoonotic disease that threatens both human and animal health. Due to the paucity of experimental animal models, little is known about how host factors interface with bacterial components and affect pathogenesis. Here, we used *Drosophila melanogaster*, in conjunction with the biosafety level 2 (BSL2) Nine Mile phase II (NMII) clone 4 strain of *C. burnetii*, as a model to investigate host and bacterial components implicated in infection. We demonstrate that adult *Drosophila* flies are susceptible to *C. burnetii* NMII infection and that this bacterial strain, which activates the immune deficiency (IMD) pathway, is able to replicate and cause mortality in the animals. We show that in the absence of Eiger, the only known tumor necrosis factor (TNF) superfamily homolog in *Drosophila*, *Coxiella*-infected flies exhibit reduced mortality from infection. We also demonstrate that the *Coxiella* type 4 secretion system (T4SS) is critical for the formation of the *Coxiella*-containing vacuole and establishment of infection in *Drosophila*. Altogether, our data reveal that the *Drosophila* TNF homolog Eiger and the *Coxiella* T4SS are implicated in the pathogenesis of *C. burnetii* in flies. The *Drosophila*/NMII model mimics relevant aspects of the infection in mammals, such as a critical role of host TNF and the bacterial T4SS in pathogenesis. Our work also demonstrates the usefulness of this BSL2 model to investigate both host and *Coxiella* components implicated in infection.

KEYWORDS Q fever, innate immunity, IMD, TNF, Eiger, NMII, pathogenesis, T4SS, tumor necrosis factor

Coxiella burnetii is an obligate intracellular Gram-negative bacterium and the causative agent of the zoonosis Q fever (1). Acute *C. burnetii* infection in humans is characterized primarily by influenza-like symptoms and pneumonia. Domestic ruminants act as reservoir hosts of *C. burnetii* and have been implicated in several outbreaks of Q fever worldwide (1–3). Based on morbidity, low infectious dose, and the environmental stability of the organism, the U.S. Centers for Disease Control and Prevention (CDC) has designated *C. burnetii* a category B biological weapon agent (4). *C. burnetii* presents two antigenic forms: a pathogenic phase I variant and an attenuated phase II variant that has a truncated O chain in its lipopolysaccharide (5, 6). *C. burnetii* phase I is associated with Q fever, whereas phase II does not cause disease in immunocompetent hosts (7–9). The Nine Mile phase II (NMII) clone 4/RSA439 is an attenuated strain of *C. burnetii* derived from the virulent Nine Mile phase I (NMI) strain through repeated passages in embryonated eggs (5). Although attenuated in immunocompetent hosts, the NMII strain has been shown to be virulent to SCID mice (10) and to cause fever in gamma interferon knockout (IFN- $\gamma^{-/-}$) and Toll-like receptor 2 knockout (TLR2 $^{-/-}$) mice (11). Because *C. burnetii* NMI and NMII strains present similar replication kinetics in tissue culture models, the NMII strain has been used as a safer option for investigating *Coxiella* pathogenesis *in vitro* (12–17). Recent studies using *C. burnetii* NMII have

Received 24 March 2017 Accepted 17 April 2017

Accepted manuscript posted online 24 April 2017

Citation Bastos RG, Howard ZP, Hiroyasu A, Goodman AG. 2017. Host and bacterial factors control susceptibility of *Drosophila melanogaster* to *Coxiella burnetii* infection. Infect Immun 85:e00218-17. <https://doi.org/10.1128/AI.00218-17>.

Editor Craig R. Roy, Yale University School of Medicine

Copyright © 2017 American Society for Microbiology. All Rights Reserved.

Address correspondence to Alan G. Goodman, agoodman@vetmed.wsu.edu.

R.G.B. and Z.P.H. contributed equally to this work.

revealed that the bacterial type 4 secretion system (T4SS) and its secreted components are *Coxiella* virulence factors (13, 15, 17, 18).

In order to better address *Coxiella*-host interactions, a reliable immunocompetent-host model suitable for biosafety level 2 (BSL2) is needed as an alternative, since animal models that utilize virulent phase I strains require BSL3 facilities. Despite recent progress in understanding *Coxiella* pathogenesis, host mechanisms associated with the control of infection and bacterial factors implicated in replication and establishment of infection remain largely unknown. Although *C. burnetii* has been detected in tick populations worldwide (19–21), the role of ticks in the epidemiology of Q fever remains unclear (22). A recent study demonstrated that *C. burnetii* has emerged from *Coxiella*-like endosymbiont organisms found in ticks, revealing evidence of how the bacterium evolved from arthropods to infect mammalian cells by the acquisition of virulence factors (23). Another study used larvae of the greater wax moth, *Galleria mellonella*, to investigate antibiotic efficacy following *Coxiella* infection and the role of dotA/dotB, two components of the *Coxiella* T4SS, in establishing infection (24). The wax moth model revealed relevant information on antimicrobials and *Coxiella* biology in arthropods; however, this host system lacks the genetic malleability found in other models, such the recently described *Caenorhabditis elegans* nematode model (25) or the arthropod *Drosophila melanogaster*. Thus, a genetically tractable arthropod model that supports *Coxiella* replication would be useful in addressing the host immune response induced by *Coxiella* infection and the bacterial factors implicated in the formation of the *Coxiella*-containing vacuole (CCV) leading to the establishment of infection.

The fruit fly *D. melanogaster* is a powerful, genetically malleable model for studying host-pathogen interactions and innate immunity (26–29), bolstered by the fact that nearly 75% of human genes implicated in disease have a functional homolog in flies (30). Secretion of antimicrobial peptides (AMPs), melanization, and the phagocytic activity of hemocytes are the primary innate immune mechanisms that the flies use to combat infection (27, 31). Activation of intracellular immune pathways following infection leads to the expression of AMPs, which are small cationic molecules that disrupt pathogen homeostasis. Activation of the immune deficiency (IMD) pathway, primarily by Gram-negative bacterial infection, leads to the expression of the AMPs Drosocin, Diptericin, Cecropin, and Attacin. The Toll pathway is primarily activated by fungi and Gram-positive bacteria, resulting in the expression of the AMPs Drosomycin and Defensin (32–35). Immune signaling pathways are evolutionarily conserved among species, and the *Drosophila* IMD and Toll pathways show similarities to the mammalian tumor necrosis factor (TNF) and Toll-like receptor pathways, respectively (31). In addition to the IMD and Toll pathways, *Drosophila* Eiger, the only known TNF homolog in flies, is also activated during bacterial infection and influences host pathology and susceptibility to infection (36–40). It has been shown that Eiger contributes to the pathology induced by infection with *Salmonella enterica* serovar Typhimurium (37). Brandt et al. proposed that *Salmonella* secreted factors stimulated an Eiger-mediated immune response that is detrimental to both the bacterium and host. Interestingly, *Drosophila* Eiger mutants were significantly more susceptible to extracellular pathogens than wild-type flies (38). This study suggested that the Eiger-mediated immune response aided in the clearance of extracellular pathogens; however, mortality from intracellular-pathogen challenge was unchanged or reduced in Eiger mutants. *Drosophila* has also been used to reveal virulence factors associated with *Francisella tularensis* pathogenesis (34), gut immunocompetence during *Pseudomonas entomophila* infection (41), and phagocytic activity during *Mycobacterium marinum* infection (32). Taking the data together, the use of *Drosophila* to investigate bacterial pathogenesis and host immune responses identifies key signaling mechanisms that may lead to the development of novel therapeutics designed to control infection in natural hosts.

In this study, we used *D. melanogaster* as a model to reveal both host and bacterial factors implicated in the pathogenesis of *C. burnetii*. We demonstrate that adult *Drosophila* flies are susceptible to the NMII clone 4 strain of *C. burnetii* and that the strain is able to replicate in adult flies. While the IMD pathway was activated following

infection, bacterial growth was affected only by the loss of the IMD transcription factor Relish. We also show that Eiger mutant flies display reduced mortality to *C. burnetii*, correlated with increased levels of the antimicrobial peptide Drosocin. Finally, our results show that the T4SS is an essential factor for the establishment of *Coxiella* infection in the animals. Altogether, we demonstrate that *Drosophila* is a novel animal model to investigate *Coxiella* infection and the host immune response.

RESULTS

C. burnetii replicates in Drosophila hemocyte-derived S2 cells. To address the question of whether *Drosophila* would be a suitable model to study *Coxiella* pathogenesis, we first investigated the ability of *C. burnetii* to infect and grow in *Drosophila* hemocyte-derived S2 cells in comparison to human HeLa cells and RAW264.7 mouse macrophages. Over a period of 2 to 8 days postinfection, no significant difference in bacterial genome equivalents (GE) was observed among *Drosophila* S2 cells, mouse RAW 267.4 macrophages, and HeLa cells. However, by 10 days postinfection, HeLa cells contained significantly higher GE levels than S2 cells, while macrophages had significantly lower GE levels than both S2 and HeLa cells (Fig. 1A). *Coxiella* antigens were detected in infected S2 cells at days 1, 6, and 12 postinfection, as demonstrated by immunoblotting using a rabbit anti-*Coxiella* polyclonal antibody and by observing specific bands at ~20 and ~30 kDa (Fig. 1B). Prominent nonspecific banding was also observed at ~60 kDa, demonstrating that while the antibody is useful for Western blotting with *Drosophila*, it may not be useful for immunohistochemistry or immunoprecipitation experiments with *Drosophila* samples. Successful colonization of mammalian cells by *Coxiella* requires the formation of a specialized CCV (12, 16, 17). Confocal microscopy performed at 10 days postinfection in S2 cells infected with mCherry-expressing *C. burnetii* revealed the presence of a single large CCV (Fig. 1C). In addition, we monitored CCV formation using lysosomal-associated membrane protein 1 (LAMP1) as a marker for the late lysosome. LAMP1 surrounded the CCV at 4 days postinfection (Fig. 1D); however, to ascertain if LAMP1 is recruited to the vacuole, experiments to visualize the vacuolar membrane and determine if LAMP1 signal is enriched need to be performed. Nevertheless, these results indicate that *C. burnetii* is able to infect and replicate in a single large vacuole inside *Drosophila* hemocyte-derived S2 cells.

C. burnetii is considered an obligate intracellular bacterium, but its ability to grow *in vitro* in the absence of host cells has been recently demonstrated (42). Thus, we next performed a gentamicin protection assay to investigate the ability of *C. burnetii* to grow within *Drosophila* S2 cells. The gentamicin assay was performed using mCherry-expressing *C. burnetii*, and bacterial growth was monitored by measuring GE and mCherry intensity. *Drosophila* S2 cells were infected with mCherry-expressing *C. burnetii* (multiplicity of infection [MOI] = 100 GE/cell) in the absence of gentamicin, and then the antibiotic was added at 0.5 h or 24 h postinfection. At 10 days postinfection, significant bacterial growth was observed in cultures lacking gentamicin or to which gentamicin was added 24 h postinfection compared to cultures to which the antibiotic was added 0.5 h postinfection (Fig. 1E and F), indicating intracellular growth of *C. burnetii* in S2 cells. Representative mCherry images are shown in Fig. 1G. The lack of bacterial growth when gentamicin was added 0.5 h postinfection suggests that complete binding and invasion of *Coxiella* in S2 cells occurs within the first 30 min of infection. Finally, to determine if bacteria grown in *Drosophila* S2 cells remain infectious to mammalian cells, at 10 days postinfection, infected S2 cells were pelleted by centrifugation, followed by Dounce homogenization to lyse the S2 cells. The bacterial GE were quantified, and 100 GE/cell was used to infect HeLa cells. The level of mCherry signal was then measured over the course of 10 days (Fig. 1H). Taken together, these results show that *C. burnetii* replicates inside S2 cells in the presence of gentamicin-containing medium and is able to reinfect mammalian cells.

C. burnetii induces the expression of antimicrobial peptides in Drosophila S2 cells. After demonstrating that *C. burnetii* infects and replicates in *Drosophila* S2 cells, we investigated its ability to induce an immune response in insect cells. Initially, we




FIG 1 *C. burnetii* replicates in *Drosophila* hemocyte-derived S2 cells. (A) Cells were infected (MOI = 100 GE/cell), and comparative growth kinetics of *C. burnetii* in insect and mammalian cells were determined by qPCR. The results are presented as log GE per microgram of DNA. (B) Immunoblotting detection of *C. burnetii* antigens in *Drosophila* S2 cells at 1, 6, and 12 days postinfection (dpi) using a rabbit polyclonal antibody against *Coxiella*. Nonspecific (n.s.) banding in S2 cell lysates is denoted by the arrow. (C and D) *Drosophila* hemocyte-derived S2 cells were infected with *C. burnetii* expressing mCherry and prepared for confocal microscopy at 4 dpi. Nuclei were stained with DAPI and actin (C) or LAMP1 (D). (E to G) A gentamicin protection assay was performed to evaluate the growth of mCherry-expressing *C. burnetii* in *Drosophila* S2 cells. (E and F) At the indicated times postinfection, total DNA was collected to determine GE levels (E) or mCherry intensity was measured at five different locations of three independent wells at the indicated time points postinfection (F). (G) Representative images for each condition at 2, 6, and 10 days postinfection. (H) mCherry-expressing *Coxiella* was isolated from infected S2 cells and used to infect HeLa cells at an MOI of 100 GE/cell. The intensity of mCherry was measured over the course of 10 days, and representative images are shown. The asterisks denote statistical significance (*, $P < 0.05$). The error bars indicate standard deviations.




FIG 2 *C. burnetii* induces the expression of AMPs in S2 cells. (A to C) A luciferase reporter assay was performed to investigate the activation of the *Drosocin* (*Dro*) (A), *CecropinA1* (*CecA1*) (B), and *Defensin* (*Def*) (C) AMP promoters in S2 cells following infection. At 24 h posttransfection, the cells were infected with *C. burnetii* (MOI = 100 GE/cell), and luciferase (luc) activity was assessed at different times postinfection. The firefly luciferase activity of each sample was normalized to Actin5C-driven *Renilla* luciferase activity to correct for transfection efficiency. (D to I) *Drosophila* S2 cells were infected with *C. burnetii* (MOI = 100 GE/cell), and total RNA was collected at 4 h and 24 h postinfection to examine AMP expression. Gene expression levels for *Drosocin* (D), *CecropinA1* (E), *Defensin* (F), *Diptericin* (G), *AttacinA* (H), and *Drosomycin* (I) were determined by qRT-PCR. The relative expression of AMP was normalized to *Drosophila RplI*. The asterisks denote statistical significance (*, $P < 0.05$). The error bars indicate standard deviations.

performed a luciferase reporter assay to investigate the activation of AMP promoters in infected insect cells. The results indicated significant activity of the *CecropinA1* and *Drosocin* promoters (Fig. 2A and B). No significant activation of the *Defensin* promoter was observed (Fig. 2C). Next, we investigated AMP expression in S2 cells infected with *C. burnetii*. Similar to the promoter assay, *Drosocin* was significantly induced following *Coxiella* infection (Fig. 2D). Additionally, *CecropinA1*, *Diptericin*, and *AttacinA* (Fig. 2E, G, and H), AMP genes also regulated by the IMD pathway, were significantly upregulated in infected cells compared to uninfected controls. No significant upregulation of *Defensin* and *Drosomycin* (Fig. 2F and I), Toll pathway-specific AMPs, was observed by comparing infected and uninfected cells. These results indicate that an IMD-specific innate immune response in *Drosophila* S2 cells was activated upon infection with *C. burnetii*.

Adult *Drosophila* flies are susceptible to *C. burnetii*. *In vitro* results using *Drosophila* S2 cells allowed us to frame a rationale for *in vivo* experiments using adult flies. Therefore, our next goal was to investigate the susceptibility of adult *Drosophila* flies to *C. burnetii*. Four-day-old Oregon-R flies were infected with live (10^2 or 10^5 GE/fly) or




FIG 3 Adult *Drosophila* flies are susceptible to *C. burnetii* and elicit a host immune response. (A and B) Four-day-old Oregon-R female (A) and male (B) *Drosophila* flies were infected with live (10^2 or 10^5 GE/fly) or HK (10^5 GE/fly) *C. burnetii*, and survival was evaluated for 30 days. (C) Four-day-old adult Oregon-R flies were infected with *C. burnetii* (100 GE/fly), and bacterial levels were determined at 6 and 30 days postinfection by quantitative real-time PCR. (D) *C. burnetii* antigens were detected in infected flies at 6 and 30 days postinfection, as shown by immunoblotting using a rabbit polyclonal antibody against *Coxiella*. Biological duplicates are shown. Nonspecific (n.s.) banding from fly homogenates is denoted by the arrow. (E and F) Antimicrobial peptide levels of *Drosocin* (E) and *Defensin* (F) were determined in Oregon-R adults infected with *C. burnetii* (100 GE/fly) at 12 days postinfection. (G and H) Confocal microscopy showing mCherry-*Coxiella* invasion of hemocytes (white arrows) derived from 3rd-instar larvae infected *in vivo* (G) or *ex vivo* (H). The hemocytes expressed GFP, and the nuclei were stained with DAPI. Bars = $2 \mu\text{m}$. Numbers by arrows designate the same *Coxiella*-mCherry signal among images in the same panel. Dotted lines in insets represent where the cross-section is made. The asterisks denote statistical significance (*, $P < 0.05$). The error bars indicate standard deviations.

heat-killed (HK) (10^5 HK GE/fly) bacteria, and mortality was evaluated for a period of 30 days. The results demonstrated that both females and males are susceptible to infection (Fig. 3A and B). Mortality was dose dependent in females ($P < 0.01$), but not in males ($P = 0.95$). The data also showed that both male and female flies were resistant to HK *C. burnetii*, suggesting that mortality is associated with the presence of live bacteria (Fig. 3A and B, green curves).

After showing the susceptibility of *Drosophila* to *C. burnetii*, we investigated if the bacterial strain was able to replicate in adult flies. Four-day-old male and female

Drosophila flies were infected with 100 GE/fly, and bacterial growth was investigated by quantitative real-time PCR (qPCR) and immunoblotting. A significant increase in *Coxiella* GE was observed from day 6 to day 30 postinfection in both female and male flies (Fig. 3C). In addition, *Coxiella* antigens were detected in infected flies at days 6 and 30 postinfection, as demonstrated by immunoblotting (Fig. 3D). Similar to the immunoblot from S2 cells, a nonspecific band was observed using adult flies. Collectively, these results indicate that *C. burnetii* is able to infect and replicate in adult *Drosophila* flies.

Next, we investigated the innate immune response elicited by *C. burnetii* infection in adult *Drosophila* flies. Expression of *Drosocin* and *Defensin* is a marker for the activation of the IMD and Toll pathways, respectively. Therefore, we determined the pattern of expression of *Drosocin* and *Defensin* in 4-day-old female and male flies infected with *C. burnetii* (100 GE/fly). The results demonstrated that *Drosocin* was significantly upregulated 12 days postinfection in females and males compared to controls (Fig. 3E). No significant upregulation of *Defensin* was observed in females and males (Fig. 3F). These results suggest that the IMD pathway mediates the innate immune response of adult flies to *C. burnetii*. Collectively, the results demonstrate that adult flies are susceptible to *C. burnetii* and that the bacterial strain is able to replicate in flies, despite the activation of the IMD pathway.

Since previous results indicated that *Drosophila* hemocyte-derived S2 cells, as well as *Drosophila* animals, were capable of being infected with *Coxiella* and exhibited host responses, we next asked whether hemocytes isolated from the animals were capable of being infected with *Coxiella*. To this end, we utilized flies carrying the reporter Hml-GAL4;UAS-EGFP (upstream activation sequence-enhanced green fluorescent protein), which causes hemocytes to express green fluorescent protein (GFP). Third-instar larvae were infected with mCherry-*Coxiella*, and 24 h postinfection, hemocytes were extracted from the animals and processed for confocal microscopy (Fig. 2G). Imaging showed that *Coxiella* infects hemocytes *in vivo*. Additionally, hemocytes were extracted from third-instar larvae and subsequently infected with mCherry-*Coxiella* (Fig. 2H), showing that hemocytes can be infected *ex vivo*.

***Drosophila* mutants for PGRP-LC and Relish are more susceptible to *C. burnetii*.**

Considering that the IMD pathway is activated during infection, we next investigated the susceptibility of *Drosophila* containing loss-of-function peptidoglycan recognition protein (PGRP) LC (PGRP-LC) or the transcription factor Relish. While PGRP-LC is the upstream receptor that initiates the IMD pathway during bacterial infection, Relish is the downstream IMD transcription factor that ultimately leads to induction of AMPs. Flies containing point mutations in PGRP-LC, *PGRP-LC*⁷⁴⁵⁴ (43), and in Relish, *Rel*^{E20} (44), were used in these experiments. The results showed that *PGRP-LC*⁷⁴⁵⁴ and *Rel*^{E20} flies exhibited increased susceptibility to *C. burnetii* compared to control *w*¹¹¹⁸ flies (Fig. 4A). Control *w*¹¹¹⁸, *PGRP-LC*⁷⁴⁵⁴, and *Rel*^{E20} flies were also significantly more susceptible ($P < 0.01$) to infection with *C. burnetii* (100 GE/fly) than their respective mock-infected controls (Fig. 4B to D). Interestingly, by 20 days postinfection, we observed a significant increase in bacterial load only in Relish mutant flies, but not PGRP-LC mutant flies, compared to *w*¹¹¹⁸ flies (Fig. 4E). We then investigated the levels of expression of *Drosocin* in infected *PGRP-LC*⁷⁴⁵⁴ and *Rel*^{E20} flies to evaluate the role of the AMP in susceptibility. Control *w*¹¹¹⁸ and *PGRP-LC*⁷⁴⁵⁴ flies expressed significantly higher levels of *Drosocin* at 12 days postinfection than in mock infection, while *Rel*^{E20} flies did not exhibit induction of *Drosocin* compared to mock infection (Fig. 4F). To further corroborate these results, we utilized transgenic flies carrying RNA interference (RNAi) cassettes for PGRP-LC or Relish, ubiquitously driven by Actin5C-GAL4. Compared to control flies lacking the Actin5C-GAL4 driver, both PGRP-LC and Relish knockdown flies exhibited increased mortality, and the bacterial load was significantly increased only in Relish RNAi flies (Fig. 4G and H). Similar to the results in Relish mutant flies, Relish RNAi flies exhibited reduced levels of *Drosocin* expression compared to controls (Fig. 4I). Finally, we performed partial-rescue experiments for the PGRP-LC and Relish mutations by crossing each of the mutant lines with the *w*¹¹¹⁸ control line. Compared to flies carrying homozygous mutations in PGRP-LC or Relish, flies that were heterozygous for the




FIG 4 *Drosophila* *PGRP-LC⁷⁴⁵⁴* and *Rel^{E20}* mutants are more susceptible to *C. burnetii* NMII clone 4. (A to F) Adult *w¹¹¹⁸*, *PGRP-LC⁷⁴⁵⁴*, and *Rel^{E20}* male flies, 4 days of age, were mock infected or infected with *C. burnetii* (100 GE/fly). Percent survival was evaluated for a period of 20 days, comparing infected flies to one another (A) or mock- and *Coxiella*-infected flies for each genotype (B to D). (E) Bacterial loads were determined at 6 and 20 days postinfection by qPCR. (F) Expression of *Drosocin* in *w¹¹¹⁸*, *PGRP-LC⁷⁴⁵⁴*, and *Rel^{E20}* flies was determined at 12 days postinfection by reverse transcriptase quantitative real-time PCR, and the results were normalized to the *Drosophila Rpl* transcripts. (G to I) Four-day-old sibling adult flies carrying a UAS-induced dsRNA cassette targeting Relish (TRIP.HMS00070) or PGRP-LC (TRIP.HMS00259) with an Act5C-driven GAL4 element (GAL4 > UAS) or lacking the GAL4 element (+ > UAS) were infected with *C. burnetii* (100 GE/fly). (G) Percent survival was evaluated for a period of 30 days. (H) The bacterial loads were determined at 6, 20, and 30 dpi by qPCR. (I) Expression of *Drosocin* was determined at 12 dpi. The asterisks denote statistical significance (*, $P < 0.05$). The error bars indicate standard deviations.

mutations exhibited decreased mortality during *C. burnetii* infection (see Fig. S1 in the supplemental material). Altogether, the data indicate that flies with a loss-of-function mutation in PGRP-LC or Relish are more susceptible to *C. burnetii* than control flies, suggesting that the presence of a functional IMD pathway protects the animals from mortality during infection. Additionally, decreased expression of *Drosocin* in infected loss-of-function or knockdown Relish flies was correlated with an increased bacterial load.

Eiger-deficient *Drosophila* flies are less susceptible to *C. burnetii*. It has been demonstrated in mammals that the pathogenesis of *Coxiella* is associated, in part, with overexpression of proinflammatory cytokines, such as TNF- α and interleukin 1 β (IL-1 β) (45). While no *Drosophila* homologs have been identified for IL-1 β , Eiger has been identified as the only known TNF superfamily ligand homolog in the flies (36). Therefore, we next infected Eiger mutant *Drosophila* flies with *C. burnetii* to investigate the underlying mechanism of susceptibility. Eiger mutant males, *egr^{1/3}*, a cross between the point mutation Eiger mutants *egr¹* and *egr³* previously described (36), were infected with *C. burnetii* NMII clone 4 (100 GE/fly), and mortality was evaluated for a period of 20 days. No significant mortality was observed in the *Coxiella*-infected *egr^{1/3}* flies compared to mock-infected controls ($P = 0.26$), but infected Eiger mutant flies showed decreased mortality compared to infected control *w¹¹¹⁸* flies (Fig. 5A). Interestingly, no significant difference in the bacterial load was observed between *w¹¹¹⁸* and Eiger mutant flies (Fig. 5B), suggesting a dissociation between mortality and bacterial load.




FIG 5 Eiger mutant *Drosophila* flies display tolerance for *C. burnetii*. (A to C) Adult w^{1118} and Eiger mutant ($egr^{1/3}$) male flies, 4 days of age, were mock infected or infected with *C. burnetii* (100 GE/fly). (A) Mortality was significantly increased ($P < 0.01$) in w^{1118} flies compared to Eiger mutant flies. (B) *Coxiella* GE was quantified at 6 and 20 days postinfection by qPCR. (C) Levels of *Drosocin* were measured in Eiger mutant flies and control w^{1118} flies at 12 days postinfection. (D to F) Four-day-old sibling adult flies carrying a UAS-induced dsRNA cassette targeting Eiger (TRiP.HMC03963) with an Actin5C-driven GAL4 element (GAL4 > UAS-egr RNAi) or lacking the GAL4 element (+ > UAS-egr RNAi) were infected with *C. burnetii* (100 GE/fly). (D) Percent survival was evaluated for a period of 30 days. (E) Bacterial loads were determined at 6, 20, and 30 days postinfection by qPCR. (F) Expression of *Drosocin* was determined at 12 days postinfection. The asterisks denote statistical significance (*, $P < 0.05$). The error bars indicate standard deviations.

Nevertheless, levels of *Drosocin* expression were significantly upregulated ($P < 0.05$) in Eiger mutant flies at 12 days postinfection compared to control w^{1118} flies (Fig. 5C), indicating activation of the IMD pathway in Eiger mutant flies. To support these results, we utilized transgenic flies carrying an RNAi cassette for Eiger, ubiquitously driven by Actin5C-GAL4. Compared to control flies lacking the Actin5C-GAL4 driver, Eiger knock-down flies exhibited reduced mortality yet similar levels of bacterial load (Fig. 5D and E). Similar to the results in $egr^{1/3}$ flies, Eiger knockdown flies exhibited increased levels of *Drosocin* induction compared to control flies (Fig. 5F). Finally, levels of Eiger induction were not significantly altered during *C. burnetii* infection (see Fig. S2 in the supplemental material), suggesting that the effects of Eiger on the host during infection are posttranscriptional, similar to those observed during *S. Typhimurium* infection (37). Collectively, the data indicate that Eiger mutant flies are more resistant to *C. burnetii* infection. Considering the absence of mortality in infected Eiger mutant flies and the fact that no difference in bacterial load was observed between Eiger mutant and wild-type flies, the data suggest that Eiger mutant flies were able to limit the impact of infection and display tolerance for *C. burnetii* infection.

The T4SS of *Coxiella* is implicated in the establishment of infection in *Drosophila*. Successful colonization of mammalian cells by *C. burnetii* requires the formation of a single CCV that is actively controlled by the bacterial T4SS and its secreted factors (46–48). Consequently, the T4SS and its secreted factors have been described as a novel virulence factor of *Coxiella* in mammals (16, 17, 49). We used *Drosophila* S2 cells and adult flies to investigate the role of the T4SS during *C. burnetii* infection. We infected S2 cells with the control background strain of *C. burnetii* (NMII clone 4) or the $\Delta dotA$ or $\Delta pmrA$ mutant and evaluated bacterial growth. While *dotA* encodes structural components of the T4SS, *pmrA* acts as a regulatory element for the proper expression of *Dot/Icm* genes (16, 17). At 10 days postinfection, both $\Delta dotA$ and $\Delta pmrA$ mutants exhibited reduced levels in S2 cells compared to the control background strain (Fig. 6A). However, $\Delta pmrA$ growth from baseline was comparable to that of the control strain. The differences in GE observed between the $\Delta dotA$ and $\Delta pmrA$ mutants may be due to the fact that *DotA* is a structural component of the T4SS while *PmrA* is a regulatory factor. Additionally, fluorescence microscopy of S2 cells infected with GFP-expressing *C. burnetii* or mutant bacteria revealed that the $\Delta dotA$ and $\Delta pmrA$ mutants were localized




FIG 6 The *C. burnetii* type 4 secretion system is essential for establishment of infection in *Drosophila*. (A) S2 cells were infected with NMII clone 4 or the $\Delta dotA$ or $\Delta pmrA$ mutant (MOI = 100 GE/cell), and bacterial growth was assessed by qPCR. (B) S2 cells were infected with NMII clone 4 or the $\Delta dotA$ and $\Delta pmrA$ mutant expressing GFP. CCV formation was observed by confocal microscopy at 6 days postinfection. (C) *Coxiella* antigens were examined in S2 cells by immunoblotting using an anti-*Coxiella* polyclonal antibody at 6 and 12 days following infection with NMII clone 4 or the $\Delta dotA$ and $\Delta pmrA$ mutants. Nonspecific (n.s.) banding in S2 cell lysates is denoted by the arrow. (D) Four-day-old adult Oregon-R flies were infected with 100 GE/fly of NMII clone 4 or the $\Delta dotA$ or $\Delta pmrA$ mutant, and mortality was monitored for 30 days. The asterisks denote statistical significance (*, $P < 0.05$). The error bars indicate standard deviations.

in small, dispersed vacuoles, which is in contrast to infection with the control background strain, which localizes in a single large vacuole (Fig. 6B). In addition, *Coxiella* antigens were not detected in S2 cells infected with $\Delta dotA$ and $\Delta pmrA$ mutants by 12 days postinfection, as demonstrated by immunoblotting (Fig. 6C). Together these results show that a pathogen-specific process, namely, the T4SS, is required for the formation of a large CCV and sustained bacterial replication. To investigate the role of the T4SS *in vivo*, we infected adult Oregon-R flies with the *C. burnetii* background strain or the $\Delta dotA$ or $\Delta pmrA$ mutant (100 GE/fly), and mortality was evaluated. The flies succumbed to infection with the background strain; however, no significant mortality was observed in flies infected with the $\Delta dotA$ or $\Delta pmrA$ mutant, indicating that the T4SS is critical for the establishment of infection *in vivo* in arthropods (Fig. 6D). While Fig. 6A shows that the $\Delta pmrA$ mutant is less infectious at early time points in S2 cells and grows as rapidly as the control strain, it does not grow in a single large vacuole, intracellular antigens are ultimately cleared, and it does not cause mortality in wild-type flies, similar to $\Delta dotA$. Altogether, considering that $\Delta dotA$ and $\Delta pmrA$ mutants do not have a functional T4SS, our results indicate that this *Coxiella* secretion system is essential for the formation of the CCV and establishment of infection in arthropods.

DISCUSSION

In the present study, we describe the use of *D. melanogaster* as a model to investigate host and bacterial factors implicated in *C. burnetii* infection. By using this model, we demonstrate that adult flies are susceptible to the BSL2 Nine Mile phase II clone 4 strain of *C. burnetii*. We also show that this *Coxiella* strain replicates in flies, despite the activation of the IMD pathway, a canonical immune pathway of *Drosophila* implicated in the control of infection with Gram-negative bacteria. Our data indicate that Eiger, a *Drosophila* TNF superfamily homolog, contributes to mortality of adult flies infected with *C. burnetii* and that Eiger mutant flies are less susceptible to infection. We also demonstrate that the *Coxiella* T4SS is essential for CCV formation and the establishment of infection in the *Drosophila* model.

A variety of animal models have been used to investigate the pathogenesis of *Coxiella*, including mice, guinea pigs, and nonhuman primates (50–55). Considering that immunocompetent hosts are resistant to the *Coxiella* phase II strains, most animal studies require the use of phase I virulent strains, which requires BSL3 facilities (4). Other animal and avirulent bacterial models, particularly those suitable for BSL2, represent safer alternatives to investigate how host and bacterial factors interface and affect the pathogenesis of *C. burnetii*. Here, we present *Drosophila* as a genetically tractable host model to study *Coxiella* infection that complements previous work performed in mammalian and other invertebrate models (23–25). The malleability of the *C. elegans* and *Drosophila* models makes them applicable to studies in mammalian systems, and *Drosophila* can be used to identify novel arthropod genetic variants implicated in susceptibility to *C. burnetii* infection that have homologous mammalian counterparts. An additional advantage of this model shown in our study is that wild-type immunocompetent *Drosophila* flies succumb to *C. burnetii* NMII clone 4, the only strain of *Coxiella* exempt from BSL3 regulations. Therefore, *Drosophila*, in conjunction with *C. burnetii*, emerges as an *in vitro* and *in vivo* system to study both host and bacterial factors implicated in infection.

The *Drosophila* IMD signaling pathway is activated in flies to respond to infection with Gram-negative bacteria (27). Bacterial peptidoglycans are sensed by PGRPs, such as PGRP-LC and PGRP-LE. This signal activates the IMD pathway nuclear factor Relish, which translocates to the nucleus, leading to the expression of AMPs, particularly Drosocin, Cecropin, Attacin, and Diptericin (43, 56). Here, we show that *C. burnetii* activates the IMD pathway, which led to significant induction of Drosocin in infected cells and adult flies. It has been demonstrated that continuous activation of AMPs under the control of the IMD signaling pathway leads to relative resistance to *F. tularensis*, a facultative intracellular Gram-negative bacterium that is closely related to *C. burnetii* (57). The study demonstrated that flies defective in the IMD pathway succumb rapidly to *Francisella* infection (34). Here, we show similar results, as the *PGRP-LC*⁷⁴⁵⁴ and *Rel*^{E20} mutant flies showed significantly more susceptibility to infection than control *w*¹¹¹⁸ flies. However, the *Coxiella* load was affected only in Relish mutants, which was correlated with a significant decrease in *Drosocin* expression in Relish mutant and RNAi flies. Previously, it was shown that *Francisella* is sensitive to *Drosophila* AMPs and grows to higher titers in Relish mutant flies (34). Similarly, we found that the *Coxiella* load was increased in Relish mutant flies, which exhibited a loss of AMP expression. However, PGRP-LC mutant flies did not exhibit increased bacterial loads or as significant a decrease in AMP induction. This suggests that once *Coxiella* is replicating intracellularly, the PGRP-LC pathway is less active and *Coxiella* activates Relish for subsequent AMP induction through an alternative mechanism.

It has been shown that phase I and phase II strains of *C. burnetii* show similar growth rates in mammalian cells (12–17). We demonstrate that *C. burnetii* shows growth kinetics in *Drosophila* S2 cells similar to those in HeLa cells and mouse macrophages. *Drosophila* hemocytes have been shown to be an appropriate, genetically amenable model for analyzing phagosome maturation (58). Localization of LAMP1 in *Leishmania*-containing vacuoles has been shown in *Drosophila* S2 cells, confirming that the fly cells

maintain the *Leishmania* parasite within compartments that share characteristics of phagolysosomes, as previously shown in mammalian cells (59, 60). In *Coxiella* infection of mammalian cells, following internalization, the nascent CCV proceeds through the default endocytic pathway and ultimately fuses with the lysosomal compartment (61). The mature CCV is then decorated with late vacuolar markers, such as Rab7, LAMP1, LAMP2, and LAMP3, and autophagosome markers, such as LC3 and Rab24 (61–65). We show that, similar to mammalian cells, LAMP1 surrounds the CCV at 4 days postinfection, suggesting that the default endocytic pathway of infected *Drosophila* S2 cells was not disturbed by infection. Further experimentation is needed to determine definitively if LAMP1 is recruited to the CCV membrane. Our results also validate *Drosophila* S2 cells as a hemocyte system to investigate the intracellular trafficking of *Coxiella* in arthropod cells.

The *Drosophila* host factor Eiger, the only known TNF homolog in *Drosophila*, contributes to pathology induced during infection with *S. Typhimurium* (38). Eiger activates the JNK pathway and induces the expression of apoptosis genes implicated in the susceptibility of flies to infection (36–38). We found that the *Drosophila* Eiger mutants did not succumb to infection with *C. burnetii*, suggesting that the TNF homolog may contribute to pathogenesis and consequently mortality in the fly model. It was shown that knocking down Eiger expression in the fat body leads to an increase in survival after *S. Typhimurium* infection, but it had no effect on the bacterial load, indicating an increase in host tolerance (39). Interestingly, no difference in *Coxiella* growth was observed in Eiger mutant flies compared to control *w¹¹¹⁸* flies, indicating dissociation between mortality and bacterial growth in these animals. Two recent studies have shown that in mouse bone marrow-derived macrophages there is production of TNF (66, 67). Additionally, cells lacking TLR2 or its downstream signaling components exhibited reduced TNF production and increased levels of *Coxiella* (66). While we did not observe induction of Eiger during infection, we observed an increase in *Drosocin* induction in Eiger mutant flies compared to the control flies, perhaps as a compensatory mechanism, similar to that observed during *S. Typhimurium* infection (38). Together, our data suggest that Eiger mutant flies were able to limit pathogenesis by becoming tolerant of *C. burnetii*, which was associated with increased AMP induction.

In mammalian cells, the T4SS system and its secreted factors are required for intracellular replication of *C. burnetii* (13, 16, 17, 47). It was also recently shown that the *Coxiella* T4SS is required for bacterial replication in hemocytes of the greater wax moth, *G. mellonella* (24). Here, we expanded that knowledge by demonstrating that $\Delta dotA$ and $\Delta pmrA$ mutants, both of which lack a functional T4SS, do not establish a productive infection *in vitro* and *in vivo* in the *Drosophila* model. Our results indicate that following infection, the T4SS mutants locate in small, dispersed vacuoles inside *Drosophila* hemocyte-derived S2 cells. In contrast, wild-type bacteria form a single large intracellular CCV. Taken together, these data indicate that the *Coxiella* T4SS is essential for efficient formation of the CCV in arthropod cells, as previously described for mammalian cells (13, 16, 17, 47).

In conclusion, this work demonstrates the usefulness of *D. melanogaster* as a novel model to investigate host and bacterial components implicated in *Coxiella* infection. Our results using *Drosophila* corroborated relevant aspects of *Coxiella* infection previously shown in *G. mellonella*, *C. elegans*, and tick cells (24–26), such as CCV formation and the role of the T4SS in replication in an arthropod model. Using adult flies, we were able to demonstrate that the *Drosophila* TNF homolog, Eiger, is implicated in susceptibility to infection. We also demonstrated that Eiger mutant flies were able to tolerate high levels of *C. burnetii*, similar to the levels in control flies, while exhibiting increased survival and AMP induction similar to that observed during *S. Typhimurium* infection (38). Thus, *Drosophila* serves as a valuable genetically tractable model for investigating host and bacterial mechanisms associated with pathogenesis and the control of infection. This model is applicable and complementary to studies in mammalian systems to decipher the host response and life cycle of *Coxiella* in the arthropod host.

MATERIALS AND METHODS

C. burnetii, insect cells, and mammalian cells. Wild-type and GFP- or mCherry-expressing *C. burnetii* NMII clone 4 RSA439 bacteria, generous gifts from Robert A. Heinzen (Rocky Mountain Laboratories, NIH, Hamilton, MT), were propagated in acidified citrate cysteine medium 2 as previously described (42). *C. burnetii* mutants for *dotA* ($\Delta dotA$) and *pmrA* ($\Delta pmrA$), encoding two components of the bacterial T4SS, expressing GFP were also provided by R. A. Heinzen. The mutant strains were propagated as previously described (16, 17). All *Coxiella* infections utilized the avirulent NMII clone 4 strain, which is exempt from the U.S. CDC select agent regulations and suitable for work at BSL2. *C. burnetii* stocks were quantified by measuring bacterial GE using qPCR as previously described (12, 68). The rabbit polyclonal antibody against *Coxiella* phase II antigens that was used for immunoblots in this study was provided by R. A. Heinzen. *Drosophila* hemocyte-derived S2 cells were maintained at 28°C in tissue culture flasks containing Schneider's *Drosophila* medium (Gibco, Waltham, MA) supplemented with 10% heat-inactivated fetal bovine serum (FBS) (HyClone), 100 U/ml of penicillin, 100 μ g/ml of streptomycin, and 0.25 μ g/ml of amphotericin B (Fungizone) antimycotic (Life Technologies, Waltham, MA). RAW267.4 mouse macrophages and HeLa cells (ATCC) were maintained at 37°C and 5% CO₂ in tissue culture flasks containing Dulbecco's modified Eagle's medium (DMEM) (Gibco) supplemented with 10% heat-inactivated FBS, 100 U/ml of penicillin, 100 μ g/ml of streptomycin, and 0.25 μ g/ml of amphotericin B antimycotic.

Bacterial infections in vitro. S2 cells were plated at 2×10^5 cells per well in 24-well plates containing Schneider's *Drosophila* medium with 10% FBS without antibiotic, and RAW267.4 mouse macrophages or HeLa cells were plated at 10^5 cells per well in 24-well plates containing DMEM-10% FBS without antibiotic. The following day, the cells were infected with *C. burnetii* (MOI = 100 GE/cell) in DMEM containing 2% FBS without antibiotics. The insect and mammalian cells were collected at different time points postinfection to investigate bacterial growth by qPCR, as previously described (12, 68). Total RNA from the insect cells was also collected at different time points postinfection for quantitative reverse transcriptase PCR (qRT-PCR) to assess the expression of AMPs. For the gentamicin protection assay, S2 cells were plated at 2×10^5 cells in 96-well plates containing Schneider's *Drosophila* medium with 10% FBS without antibiotic. The following day, the cells were infected with *C. burnetii* expressing mCherry (MOI = 100 GE/cell) in Schneider's medium containing 2% FBS without antibiotics. Gentamicin (10 μ g/ml; Gibco) was then added at 0.5 h or 24 h postinfection. The gentamicin-containing medium was replaced every 2 days, and bacterial growth was assessed by examining mCherry intensity using a Cytation 3 imaging reader (Biotek, Winooski, VT).

Luciferase reporter assay. Activation of *CecropinA1*, *Drosocin*, and *Defensin* promoters in S2 cells following *C. burnetii* infection was performed by luciferase reporter assay. The cells were transiently transfected with the *CecropinA1* (69), *Drosocin* (70), or *Defensin* (71) promoter cloned into pGL4.10 (Promega), along with the promoter for *Actin5C* cloned into pRL (Promega, Madison, WI) as an internal transfection control, using Cellfectin II (Life Technologies). Six hours posttransfection, the medium was replaced with fresh growth medium, and 16 h following the medium change, the cells were infected with *C. burnetii* (MOI = 100 GE/cell) diluted in medium containing 2% FBS, and the firefly luciferase activity was assessed at different time points postinfection.

Confocal microscopy. The infected cells were fixed for 1 h in 2% formaldehyde, followed by permeabilization for 10 min in 0.1% Triton X-100. The cells were blocked in phosphate-buffered saline (PBS) containing 10% FBS and incubated with antibodies against actin (Sigma A2066) or LAMP-1 (Abcam 30687) for 1 h at room temperature. The cells were washed and incubated with Alexa Fluor-488 (Thermo Fisher A-11008)-conjugated secondary antibodies for 1 h at room temperature. The cells were washed, incubated with DAPI (4',6'-diamidino-2-phenylindole) (Sigma D9542) for 15 min, and mounted onto microscope slides. Images were obtained using a Leica SP8-X White Light Laser point scanning confocal microscope and analyzed using Leica Application Suite X.

D. melanogaster and infections. The *Drosophila w¹¹¹⁸*, Oregon-R, Hml-EGFP driver ($w^{1118};P\{wHml-GAL4\Delta\}2,P\{UAS-2xEGFP\}AH2$), Act5C-GAL4 driver ($y^1w^*;P\{Act5C-GAL4\}25FO1/CyO$), tub-GAL4 driver ($y^1w^*;P\{tubP-GAL4\}LL7/TM3,Sb^1,Ser^1$), Double balancer ($w^*;Kr^{f-1}/CyO;D^1/TM3,Ser^1$), Relish RNAi ($y^1v^1;;P\{yTRIP.HMS00070\}attP2$), Eiger RNAi ($y^1sc^*v^1;P\{TRIP.HMC03963\}attP40$), PGRP-LC RNAi ($y^1sc^*v^1;;P\{TRIP.HMS00259\}attP2$), *PGRP-LC⁷⁴⁵⁴* (43), *Rel^{E20}* (44), *Eiger¹*, and *Eiger³* (36) strains were used in this study. RNAi knockdown was performed using sibling progeny from crosses between the parental Act5C-GAL4 driver line and the corresponding RNAi lines. Progeny flies carrying the CyO balancer were used as control flies. All the fly strains were grown in standard meal agar fly food and maintained at 23°C and 68% humidity. Fly stocks were cleared of *Wolbachia* infection by feeding two generations with standard fly food containing 0.05 mg/ml tetracycline (Sigma).

Adult flies were injected with live bacteria (10^2 or 10^5 GE/fly) or HK (98°C for 1 h) bacteria (10^5 GE/fly). For injections, flies were anesthetized with CO₂ and injected with 23 nl of bacteria or PBS using a pulled 0.53-mm glass needle and an automatic nanoliter injector (Drummond Scientific, Broomall, PA). Individual flies were injected at the ventrolateral surface of the fly thorax and placed into new vials. Unless otherwise noted, adult male flies were used for all experiments. Third-instar larvae from Hml-GAL4>UAS-EGFP flies were infected with mCherry-expressing bacteria using a 0.001-mm tungsten needle while the larvae were in a pool of 10^9 GE/ml of bacteria for 1 h. Hemocytes were isolated by mechanical dissection as previously described (72). After the injections, the adult flies were monitored daily for mortality and collected at different times postinfection to assess the bacterial load and expression of AMPs. Survival curves were performed using a minimum of 80 flies per condition, including at least two experimental replicates. The bacterial load was determined by qPCR in 3 biological replicates of flies homogenized in PBS as described previously (12, 68).

Expression of antimicrobial peptides. The relative expression of AMPs in *Drosophila* S2 cells and in adult flies was determined by qRT-PCR. For S2 cells, total RNA was extracted using the GeneJet RNA purification kit (Thermo Scientific). Samples were treated with DNase I (Invitrogen), and cDNA was synthesized using the iScript Reverse Transcriptase kit (Bio-Rad, Hercules, CA). For adult *Drosophila* flies, total RNA from infected and uninfected flies was isolated at different time points postinfection from at least 2 biological replicates containing 3 flies in each sample. The flies were homogenized in solution D (4 M guanidinium thiocyanate, 25 mM sodium citrate, 0.5% sarcosyl, 0.1 M 2-mercaptoethanol). RNA extraction, DNase treatment, and cDNA synthesis were performed as described above. Reverse transcriptase quantitative real-time PCR was performed using SsoFast SYBR green PCR master mix (Bio-Rad) in an ABI 7500 Fast thermocycler using 60°C as the annealing temperature. Expression of the following genes was evaluated using the specific primers given in parentheses: *Drosomycin* (5-CGTGAGAACCTT TCCAATATGATG-3 and 5-TCCCAGGACCACCAGCAT-3), *Diptericin* (5-GCTGCGCAATCGCTTCTACT-3 and 5-TGGTGGAGTGGGCTTCATG-3), *AttacinA* (5-CACAATGTGGTGGGTGAGG-3 and 5-GGCACCATGACCAGCAT-3), *Drosocin* (5-GCACAATGAAGTTCACCATCGT-3 and 5-CCACACCCATGGCAAAAAC-3), *Defensin* (5-GCCAG AACGAGCCACAT-3 and 5-CGGTGTGGTTCAGTCCA-3), *CecropinA1* (5-GGACAATCGGAAGCTGGTT-3 and 5-TGTGCTGACCAACAGTTC-3), and *Eiger* (5-GATGTCTGGATTCCATTGC-3 and 5-TAGTCTGCGCCAACATC ATC-3) (37). The *Drosophila* RNA polymerase II gene (*Rpl1*) (5-TTGACGTAAGCATCACCTG-3 and 5-GAAGC GTTCTCCAAACGAG-3) was utilized as an internal control for gene induction.

Immunoblotting. Flies were homogenized in radioimmunoprecipitation assay (RIPA) buffer (25 mM Tris-HCl [pH 7.6], 150 mM NaCl, 1 mM EDTA, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS, 1 mM Na₃VO₄, 1 mM NaF, 0.1 mM phenylmethylsulfonyl fluoride [PMSF], 10 μM aprotinin, 5 μg/ml leupeptin, 1 μg/ml pepstatin A). Total protein was determined using the bicinchoninic acid (BCA) assay (Pierce, Waltham, MA). Equal amounts of protein were subjected to SDS-PAGE. The proteins were transferred to a polyvinylidene difluoride (PVDF) membrane and blocked in 5% bovine serum albumin (BSA) in 0.1% Tween 20–Tris-buffered saline. The membrane was incubated with rabbit anti-*Coxiella* phase II antibody (1:10,000) overnight at 4°C. Antibody-bound proteins were detected using anti-rabbit secondary antibodies conjugated to horseradish peroxidase. The blots were developed by chemiluminescence using luminol enhancer solution (ThermoFisher).

Statistics. A two-tailed Student *t* test assuming unequal variance was utilized to compare means of quantitative data. Mortality curves were analyzed by the log-rank (Mantel-Cox) test using GraphPad Prism (GraphPad Software, Inc.).

SUPPLEMENTAL MATERIAL

Supplemental material for this article may be found at <https://doi.org/10.1128/IAI.00218-17>.

SUPPLEMENTAL FILE 1, PDF file, 0.2 MB.

ACKNOWLEDGMENTS

We thank Michael E. Konkel and Laura R. H. Ahlers for critical review of the manuscript. We thank Anders Omsland for propagating *Coxiella* strains.

This investigation was supported by funds from Washington State University and National Institutes of Health Public Health Service grant R00AI106963 (to A.G.G.).

The contents are solely our responsibility and do not necessarily represent the official views of the NIH.

REFERENCES

- Maurin M, Raoult D. 1999. Q fever. *Clin Microbiol Rev* 12:518–553.
- Schimmer B, Morroy G, Dijkstra F, Schneeberger PM, Weers-Pothoff G, Timen A, Wijkman C, van der Hoek W. 2008. Large ongoing Q fever outbreak in the south of The Netherlands, 2008. *Euro Surveill* 13:18939.
- Sondgeroth KS, Davis MA, Schlee SL, Allen AJ, Evermann JF, McElwain TF, Baszler TV. 2013. Seroprevalence of *Coxiella burnetii* in Washington State domestic goat herds. *Vector Borne Zoonotic Dis* 13:779–783. <https://doi.org/10.1089/vbz.2013.1331>.
- Madariaga MG, Rezaei K, Trenholme GM, Weinstein RA. 2003. Q fever: a biological weapon in your backyard. *Lancet Infect Dis* 3:709–721. [https://doi.org/10.1016/S1473-3099\(03\)00804-1](https://doi.org/10.1016/S1473-3099(03)00804-1).
- Hackstadt T, Peacock MG, Hitchcock PJ, Cole RL. 1985. Lipopolysaccharide variation in *Coxiella burnetii*: intrastain heterogeneity in structure and antigenicity. *Infect Immun* 48:359–365.
- Hoover TA, Culp DW, Vodkin MH, Williams JC, Thompson HA. 2002. Chromosomal DNA deletions explain phenotypic characteristics of two antigenic variants, phase II and RSA 514 (crazy), of the *Coxiella burnetii* nine mile strain. *Infect Immun* 70:6726–6733. <https://doi.org/10.1128/IAI.70.12.6726-2733.2002>.
- Zhang G, Russell-Lodrigue KE, Andoh M, Zhang Y, Hendrix LR, Samuel JE. 2007. Mechanisms of vaccine-induced protective immunity against *Coxiella burnetii* infection in BALB/c mice. *J Immunol* 179:8372–8380. <https://doi.org/10.4049/jimmunol.179.12.8372>.
- Andoh M, Russell-Lodrigue KE, Zhang G, Samuel JE. 2005. Comparative virulence of phase I and II *Coxiella burnetii* in immunodeficient mice. *Ann N Y Acad Sci* 1063:167–170. <https://doi.org/10.1196/annals.1355.026>.
- Andoh M, Naganawa T, Hotta A, Yamaguchi T, Fukushima H, Masegi T, Hirai K. 2003. SCID mouse model for lethal Q fever. *Infect Immun* 71:4717–4723. <https://doi.org/10.1128/IAI.71.8.4717-4723.2003>.
- Islam A, Lockhart M, Stenos J, Graves S. 2013. The attenuated nine mile phase II clone 4/RSA439 strain of *Coxiella burnetii* is highly virulent for severe combined immunodeficient (SCID) mice. *Am J Trop Med Hyg* 89:800–803. <https://doi.org/10.4269/ajtmh.12-0653>.
- Ochoa-Reparaz J, Sentissi J, Trunkle T, Riccardi C, Pascual DW. 2007. Attenuated *Coxiella burnetii* phase II causes a febrile response in gamma interferon knockout and Toll-like receptor 2 knockout mice and protects against reinfection. *Infect Immun* 75:5845–5858. <https://doi.org/10.1128/IAI.00901-07>.
- Howe D, Shannon JG, Winfree S, Dorward DW, Heinzen RA. 2010. *Coxiella*

- burnetii phase I and II variants replicate with similar kinetics in degradative phagolysosome-like compartments of human macrophages. *Infect Immun* 78:3465–3474. <https://doi.org/10.1128/IAI.00406-10>.
13. Newton HJ, Kohler LJ, McDonough JA, Temoche-Diaz M, Crabill E, Hartland EL, Roy CR. 2014. A screen of *Coxiella burnetii* mutants reveals important roles for Dot/Icm effectors and host autophagy in vacuole biogenesis. *PLoS Pathog* 10:e1004286. <https://doi.org/10.1371/journal.ppat.1004286>.
 14. Martinez E, Cantet F, Fava L, Norville I, Bonazzi M. 2014. Identification of OmpA, a *Coxiella burnetii* protein involved in host cell invasion, by multi-phenotypic high-content screening. *PLoS Pathog* 10:e1004013. <https://doi.org/10.1371/journal.ppat.1004013>.
 15. Larson CL, Beare PA, Voth DE, Howe D, Cockrell DC, Bastidas RJ, Valdivia RH, Heinzen RA. 2015. *Coxiella burnetii* effector proteins that localize to the parasitophorous vacuole membrane promote intracellular replication. *Infect Immun* 83:661–670. <https://doi.org/10.1128/IAI.02763-14>.
 16. Beare PA, Sandoz KM, Larson CL, Howe D, Kronmiller B, Heinzen RA. 2014. Essential role for the response regulator PmrA in *Coxiella burnetii* type 4B secretion and colonization of mammalian host cells. *J Bacteriol* 196:1925–1940. <https://doi.org/10.1128/JB.01532-14>.
 17. Beare PA, Gilk SD, Larson CL, Hill J, Stead CM, Omsland A, Cockrell DC, Howe D, Voth DE, Heinzen RA. 2011. Dot/Icm type IVB secretion system requirements for *Coxiella burnetii* growth in human macrophages. *mBio* 2:e00175-11. <https://doi.org/10.1128/mBio.00175-11>.
 18. Carey KL, Newton HJ, Luhrmann A, Roy CR. 2011. The *Coxiella burnetii* Dot/Icm system delivers a unique repertoire of type IV effectors into host cells and is required for intracellular replication. *PLoS Pathog* 7:e1002056. <https://doi.org/10.1371/journal.ppat.1002056>.
 19. Mediannikov O, Fenollar F, Socolovschi C, Diatta G, Bassene H, Molez JF, Sokhna C, Trape JF, Raoult D. 2010. *Coxiella burnetii* in humans and ticks in rural Senegal. *PLoS Negl Trop Dis* 4:e654. <https://doi.org/10.1371/journal.pntd.0000654>.
 20. Halajian A, Palomar AM, Portillo A, Heyne H, Luus-Powell WJ, Oteo JA. 2016. Investigation of Rickettsia, *Coxiella burnetii* and Bartonella in ticks from animals in South Africa. *Ticks Tick Borne Dis* 7:361–366. <https://doi.org/10.1016/j.ttbdis.2015.12.008>.
 21. Noda AA, Rodriguez I, Miranda J, Contreras V, Mattar S. 2016. First molecular evidence of *Coxiella burnetii* infecting ticks in Cuba. *Ticks Tick Borne Dis* 7:68–70. <https://doi.org/10.1016/j.ttbdis.2015.08.008>.
 22. Duron O, Sidi-Boumedine K, Rousset E, Moutailler S, Jourdain E. 2015. The importance of ticks in Q fever transmission: what has (and has not) been demonstrated? *Trends Parasitol* 31:536–552. <https://doi.org/10.1016/j.pt.2015.06.014>.
 23. Duron O, Noel V, McCoy KD, Bonazzi M, Sidi-Boumedine K, Morel O, Vavre F, Zenner L, Jourdain E, Durand P, Arnathau C, Renaud F, Trape JF, Biguezoton AS, Cremaschi J, Dietrich M, Leger E, Appelgren A, Dupraz M, Gomez-Diaz E, Diatta G, Dayo GK, Adakal H, Zoungrana S, Vial L, Chevillon C. 2015. The recent evolution of a maternally-inherited endosymbiont of ticks led to the emergence of the Q fever pathogen, *Coxiella burnetii*. *PLoS Pathog* 11:e1004892. <https://doi.org/10.1371/journal.ppat.1004892>.
 24. Norville IH, Hartley MG, Martinez E, Cantet F, Bonazzi M, Atkins TP. 2014. *Galleria mellonella* as an alternative model of *Coxiella burnetii* infection. *Microbiology* 160:1175–1181. <https://doi.org/10.1099/mic.0.077230-0>.
 25. Battisti JM, Watson LA, Naung MT, Drobish AM, Voronina E, Minnick MF. 2017. Analysis of the *Caenorhabditis elegans* innate immune response to *Coxiella burnetii*. *Innate Immun* 23:111–127. <https://doi.org/10.1177/1753425916679255>.
 26. Hoffmann JA, Hetru C, Reichhart JM. 1993. The humoral antibacterial response of *Drosophila*. *FEBS Lett* 325:63–66. [https://doi.org/10.1016/0014-5793\(93\)81414-U](https://doi.org/10.1016/0014-5793(93)81414-U).
 27. Lemaitre B, Hoffmann J. 2007. The host defense of *Drosophila melanogaster*. *Annu Rev Immunol* 25:697–743. <https://doi.org/10.1146/annurev.immunol.25.022106.141615>.
 28. Dionne MS, Schneider DS. 2008. Models of infectious diseases in the fruit fly *Drosophila melanogaster*. *Dis Model Mech* 1:43–49. <https://doi.org/10.1242/dmm.000307>.
 29. Panayidou S, Ioannidou E, Apidianakis Y. 2014. Human pathogenic bacteria, fungi, and viruses in *Drosophila*: disease modeling, lessons, and shortcomings. *Virulence* 5:253–269. <https://doi.org/10.4161/viru.27524>.
 30. Pandey UB, Nichols CD. 2011. Human disease models in *Drosophila melanogaster* and the role of the fly in therapeutic drug discovery. *Pharmacol Rev* 63:411–436. <https://doi.org/10.1124/pr.110.003293>.
 31. Hoffmann JA. 2003. The immune response of *Drosophila*. *Nature* 426:33–38. <https://doi.org/10.1038/nature02021>.
 32. Dionne MS, Ghori N, Schneider DS. 2003. *Drosophila melanogaster* is a genetically tractable model host for *Mycobacterium marinum*. *Infect Immun* 71:3540–3550. <https://doi.org/10.1128/IAI.71.6.3540-3550.2003>.
 33. Tanji T, Hu X, Weber AN, Ip YT. 2007. Toll and IMD pathways synergistically activate an innate immune response in *Drosophila melanogaster*. *Mol Cell Biol* 27:4578–4588. <https://doi.org/10.1128/MCB.01814-06>.
 34. Vonkavaara M, Telepnev MV, Ryden P, Sjostedt A, Stoven S. 2008. *Drosophila melanogaster* as a model for elucidating the pathogenicity of *Francisella tularensis*. *Cell Microbiol* 10:1327–1338. <https://doi.org/10.1111/j.1462-5822.2008.01129.x>.
 35. Vonkavaara M, Pavel ST, Holz K, Nordfelth R, Sjostedt A, Stoven S. 2013. *Francisella* is sensitive to insect antimicrobial peptides. *J Innate Immun* 5:50–59. <https://doi.org/10.1159/000342468>.
 36. Igaki T, Kanda H, Yamamoto-Goto Y, Kanuka H, Kuranaga E, Aigaki T, Miura M. 2002. Eiger, a TNF superfamily ligand that triggers the *Drosophila* JNK pathway. *EMBO J* 21:3009–3018. <https://doi.org/10.1093/emboj/cdf306>.
 37. Brandt SM, Dionne MS, Khush RS, Pham LN, Vigdal TJ, Schneider DS. 2004. Secreted bacterial effectors and host-produced Eiger/TNF drive death in a *Salmonella*-infected fruit fly. *PLoS Biol* 2:e418. <https://doi.org/10.1371/journal.pbio.0020418>.
 38. Schneider DS, Ayres JS, Brandt SM, Costa A, Dionne MS, Gordon MD, Mabery EM, Moule MG, Pham LN, Shirasu-Hiza MM. 2007. *Drosophila* Eiger mutants are sensitive to extracellular pathogens. *PLoS Pathog* 3:e41. <https://doi.org/10.1371/journal.ppat.0030041>.
 39. Mabery EM, Schneider DS. 2010. The *Drosophila* TNF ortholog Eiger is required in the fat body for a robust immune response. *J Innate Immun* 2:371–378. <https://doi.org/10.1159/000315050>.
 40. Xu J, Hopkins K, Sabin L, Yasunaga A, Subramanian H, Lamborn I, Gordesky-Gold B, Cherry S. 2013. ERK signaling couples nutrient status to antiviral defense in the insect gut. *Proc Natl Acad Sci U S A* 110:15025–15030. <https://doi.org/10.1073/pnas.1303193110>.
 41. Bou Sleiman MS, Osman D, Massouras A, Hoffmann AA, Lemaitre B, Deplancke B. 2015. Genetic, molecular and physiological basis of variation in *Drosophila* gut immunocompetence. *Nat Commun* 6:7829. <https://doi.org/10.1038/ncomms8829>.
 42. Omsland A, Cockrell DC, Howe D, Fischer ER, Virtaneva K, Sturdevant DE, Porcella SF, Heinzen RA. 2009. Host cell-free growth of the Q fever bacterium *Coxiella burnetii*. *Proc Natl Acad Sci U S A* 106:4430–4434. <https://doi.org/10.1073/pnas.0812074106>.
 43. Gottar M, Gobert V, Michel T, Belvin M, Duyk G, Hoffmann JA, Ferrandon D, Royet J. 2002. The *Drosophila* immune response against Gram-negative bacteria is mediated by a peptidoglycan recognition protein. *Nature* 416:640–644. <https://doi.org/10.1038/nature734>.
 44. Hedengren M, Asling B, Dushay MS, Ando I, Ekengren S, Wihlborg M, Hultmark D. 1999. Relish, a central factor in the control of humoral but not cellular immunity in *Drosophila*. *Mol Cell* 4:827–837. [https://doi.org/10.1016/S1097-2765\(00\)80392-5](https://doi.org/10.1016/S1097-2765(00)80392-5).
 45. Capo C, Zugun F, Stein A, Tardei G, Lepidi H, Raoult D, Mege JL. 1996. Upregulation of tumor necrosis factor alpha and interleukin-1 beta in Q fever endocarditis. *Infect Immun* 64:1638–1642.
 46. Coleman SA, Fischer ER, Howe D, Mead DJ, Heinzen RA. 2004. Temporal analysis of *Coxiella burnetii* morphological differentiation. *J Bacteriol* 186:7344–7352. <https://doi.org/10.1128/JB.186.21.7344-7352.2004>.
 47. Weber MM, Chen C, Rowin K, Mertens K, Galvan G, Zhi H, Dealing CM, Roman VA, Banga S, Tan Y, Luo ZQ, Samuel JE. 2013. Identification of *Coxiella burnetii* type IV secretion substrates required for intracellular replication and *Coxiella*-containing vacuole formation. *J Bacteriol* 195:3914–3924. <https://doi.org/10.1128/JB.00071-13>.
 48. Moffatt JH, Newton P, Newton HJ. 2015. *Coxiella burnetii*: turning hostility into a home. *Cell Microbiol* 17:621–631. <https://doi.org/10.1111/cmi.12432>.
 49. Beare PA, Sandoz KM, Omsland A, Rockey DD, Heinzen RA. 2011. Advances in genetic manipulation of obligate intracellular bacterial pathogens. *Front Microbiol* 2:97. <https://doi.org/10.3389/fmicb.2011.00097>.
 50. Gonder JC, Kishimoto RA, Castello MD, Pedersen CE, Jr, Larson EW. 1979. *Cynomolgus* monkey model for experimental Q fever infection. *J Infect Dis* 139:191–196. <https://doi.org/10.1093/infdis/139.2.191>.
 51. Kishimoto RA, Johnson JW, Kenyon RH, Ascher MS, Larson EW, Pedersen CE, Jr. 1978. Cell-mediated immune responses of guinea pigs to an inactivated phase I *Coxiella burnetii* vaccine. *Infect Immun* 19:194–198.
 52. Kishimoto RA, Gonder JC, Johnson JW, Reynolds JA, Larson EW. 1981.

- Evaluation of a killed phase I *Coxiella burnetii* vaccine in cynomolgus monkeys (*Macaca fascicularis*). *Lab Anim Sci* 31:48–51.
53. Baumgartner W, Bachmann S. 1992. Histological and immunocytochemical characterization of *Coxiella burnetii*-associated lesions in the murine uterus and placenta. *Infect Immun* 60:5232–5241.
 54. Stein A, Louveau C, Lepidi H, Ricci F, Baylac P, Davoust B, Raoult D. 2005. Q fever pneumonia: virulence of *Coxiella burnetii* pathovars in a murine model of aerosol infection. *Infect Immun* 73:2469–2477. <https://doi.org/10.1128/IAI.73.4.2469-2477.2005>.
 55. Russell-Lodrigue KE, Zhang GQ, McMurray DN, Samuel JE. 2006. Clinical and pathologic changes in a guinea pig aerosol challenge model of acute Q fever. *Infect Immun* 74:6085–6091. <https://doi.org/10.1128/IAI.00763-06>.
 56. Kurata S. 2014. Peptidoglycan recognition proteins in *Drosophila* immunity. *Dev Comp Immunol* 42:36–41. <https://doi.org/10.1016/j.dci.2013.06.006>.
 57. Champion MD. 2011. Host-pathogen o-methyltransferase similarity and its specific presence in highly virulent strains of *Francisella tularensis* suggests molecular mimicry. *PLoS One* 6:e20295. <https://doi.org/10.1371/journal.pone.0020295>.
 58. Shandala T, Lim C, Sorvina A, Brooks DA. 2013. A *Drosophila* model to image phagosome maturation. *Cells* 2:188–201. <https://doi.org/10.3390/cells2020188>.
 59. Peltan A, Briggs L, Matthews G, Sweeney ST, Smith DF. 2012. Identification of *Drosophila* gene products required for phagocytosis of *Leishmania donovani*. *PLoS One* 7:e51831. <https://doi.org/10.1371/journal.pone.0051831>.
 60. Lodge R, Descoteaux A. 2006. Phagocytosis of *Leishmania donovani* amastigotes is Rac1 dependent and occurs in the absence of NADPH oxidase activation. *Eur J Immunol* 36:2735–2744. <https://doi.org/10.1002/eji.200636089>.
 61. Heinzen RA, Scidmore MA, Rockey DD, Hackstadt T. 1996. Differential interaction with endocytic and exocytic pathways distinguish parasitophorous vacuoles of *Coxiella burnetii* and *Chlamydia trachomatis*. *Infect Immun* 64:796–809.
 62. Ghigo E, Honstetterre A, Capo C, Gorvel JP, Raoult D, Mege JL. 2004. Link between impaired maturation of phagosomes and defective *Coxiella burnetii* killing in patients with chronic Q fever. *J Infect Dis* 190:1767–1772. <https://doi.org/10.1086/425041>.
 63. Sauer JD, Shannon JG, Howe D, Hayes SF, Swanson MS, Heinzen RA. 2005. Specificity of *Legionella pneumophila* and *Coxiella burnetii* vacuoles and versatility of *Legionella pneumophila* revealed by coinfection. *Infect Immun* 73:4494–4504. <https://doi.org/10.1128/IAI.73.8.4494-4504.2005>.
 64. Romano PS, Gutierrez MG, Beron W, Rabinovitch M, Colombo MI. 2007. The autophagic pathway is actively modulated by phase II *Coxiella burnetii* to efficiently replicate in the host cell. *Cell Microbiol* 9:891–909. <https://doi.org/10.1111/j.1462-5822.2006.00838.x>.
 65. Gutierrez MG, Vazquez CL, Munafo DB, Zoppino FC, Beron W, Rabinovitch M, Colombo MI. 2005. Autophagy induction favours the generation and maturation of the *Coxiella*-replicative vacuoles. *Cell Microbiol* 7:981–993. <https://doi.org/10.1111/j.1462-5822.2005.00527.x>.
 66. Bradley WP, Boyer MA, Nguyen HT, Birdwell LD, Yu J, Ribeiro JM, Weiss SR, Zamboni DS, Roy CR, Shin S. 2016. Primary role for Toll-like receptor-driven tumor necrosis factor rather than cytosolic immune detection in restricting *Coxiella burnetii* phase II replication within mouse macrophages. *Infect Immun* 84:998–1015. <https://doi.org/10.1128/IAI.01536-15>.
 67. Cockrell DC, Long CM, Robertson SJ, Shannon JG, Miller HE, Myers L, Larson CL, Starr T, Beare PA, Heinzen RA. 2017. Robust growth of avirulent phase II *Coxiella burnetii* in bone marrow-derived murine macrophages. *PLoS One* 12:e0173528. <https://doi.org/10.1371/journal.pone.0173528>.
 68. Shannon JG, Howe D, Heinzen RA. 2005. Virulent *Coxiella burnetii* does not activate human dendritic cells: role of lipopolysaccharide as a shielding molecule. *Proc Natl Acad Sci U S A* 102:8722–8727. <https://doi.org/10.1073/pnas.0501863102>.
 69. Kylsten P, Samakovlis C, Hultmark D. 1990. The cecropin locus in *Drosophila*; a compact gene cluster involved in the response to infection. *EMBO J* 9:217–224.
 70. Charlet M, Lagueux M, Reichhart JM, Hoffmann D, Braun A, Meister M. 1996. Cloning of the gene encoding the antibacterial peptide drosocin involved in *Drosophila* immunity. Expression studies during the immune response. *Eur J Biochem* 241:699–706.
 71. Dimarcq JL, Hoffmann D, Meister M, Bulet P, Lanot R, Reichhart JM, Hoffmann JA. 1994. Characterization and transcriptional profiles of a *Drosophila* gene encoding an insect defensin. A study in insect immunity. *Eur J Biochem* 221:201–209.
 72. Petraki S, Alexander B, Bruckner K. 2015. Assaying blood cell populations of the *Drosophila melanogaster* larva. *J Vis Exp* <https://doi.org/10.3791/52733>.